Header Logo

John Segreti

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine, Division of Infectious Diseases
Address
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 7005525887

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lin MY, Stein BD, Kothadia SM, Blank S, Schoeny ME, Tomich A, Hayden MK, Segreti J. Impact of Mandatory Infectious Disease Specialist Approval on Hospital-Onset Clostridioides difficile Infection Rates and Testing Appropriateness. Clin Infect Dis. 2023 08 14; 77(3):346-350. PMID: 37157903.
      Citations:    
    2. Egbulefu FJ, Yang J, Segreti JC, Sporer SM, Chen AF, Austin MS, Della Valle CJ. Recurrent Failures After 2-Stage Exchanges are Secondary to New Organisms Not Previously Covered by Antibiotics. Arthroplast Today. 2022 Oct; 17:186-191.e1. PMID: 36254212.
      Citations:    
    3. Yang J, Parvizi J, Hansen EN, Culvern CN, Segreti JC, Tan T, Hartman CW, Sporer SM, Della Valle CJ. 2020 Mark Coventry Award: Microorganism-directed oral antibiotics reduce the rate of failure due to further infection after two-stage revision hip or knee arthroplasty for chronic infection: a multicentre randomized controlled trial at a minimum of two years. Bone Joint J. 2020 Jun; 102-B(6_Supple_A):3-9. PMID: 32475278.
      Citations:    
    4. Saeed K, Esposito S, Ascione T, Bassetti M, Bonnet E, Carnelutti A, Chan M, Lye DC, Cortes N, Dryden M, Fernando S, Gottlieb T, Gould I, Hijazi K, Madonia S, Pagliano P, Pottinger PS, Segreti J, Spera AM. Hot topics on vertebral osteomyelitis from the International Society of Antimicrobial Chemotherapy. Int J Antimicrob Agents. 2019 Aug; 54(2):125-133. PMID: 31202920.
      Citations:    
    5. Wang SK, Gilchrist A, Loukitcheva A, Plotkin BJ, Sigar IM, Gross AE, O'Donnell JN, Pettit N, Buros A, O'Driscoll T, Rhodes NJ, Bethel C, Segreti J, Charnot-Katsikas A, Singh K, Scheetz MH. Prevalence of a Cefazolin Inoculum Effect Associated with blaZ Gene Types among Methicillin-Susceptible Staphylococcus aureus Isolates from Four Major Medical Centers in Chicago. Antimicrob Agents Chemother. 2018 08; 62(8). PMID: 29891607.
      Citations:    
    6. Shimasaki T, Segreti J, Tomich A, Kim J, Hayden MK, Lin MY. Active screening and interfacility communication of carbapenem-resistant Enterobacteriaceae (CRE) in a tertiary-care hospital. Infect Control Hosp Epidemiol. 2018 09; 39(9):1058-1062. PMID: 30022738.
      Citations:    
    7. Saeed K, Esposito S, Gould I, Ascione T, Bassetti M, Bonnet E, Bouza E, Chan M, Davis JS, De Simone G, Dryden M, Gottlieb T, Hijazi K, Lye DC, Pagliano P, Petridou C, Righi E, Segreti J, Unal S, Yalcin AN. Hot topics in necrotising skin and soft tissue infections. Int J Antimicrob Agents. 2018 Jul; 52(1):1-10. PMID: 29501822.
      Citations:    
    8. Segreti J, Parvizi J, Berbari E, Ricks P, Berr?os-Torres SI. Introduction to the Centers for Disease Control and Prevention and Healthcare Infection Control Practices Advisory Committee Guideline for Prevention of Surgical Site Infection: Prosthetic Joint Arthroplasty Section. Surg Infect (Larchmt). 2017 May/Jun; 18(4):394-400. PMID: 28407472.
      Citations:    
    9. Saeed K, Dryden M, Bassetti M, Bonnet E, Bouza E, Chan M, Cortes N, Davis JS, Esposito S, Giordano G, Gould I, Hartwright D, Lye D, Marin M, Morgan-Jones R, Lajara-Marco F, Righi E, Romano CL, Segreti J, Unal S, Williams RL, Yalcin AN. Prosthetic joints: shining lights on challenging blind spots. Int J Antimicrob Agents. 2017 Feb; 49(2):153-161. PMID: 27939092.
      Citations:    
    10. Esposito S, Bassetti M, Bonnet E, Bouza E, Chan M, De Simone G, Dryden M, Gould I, Lye DC, Saeed K, Segreti J, Unal S, Yalcin AN. Hot topics in the diagnosis and management of skin and soft-tissue infections. Int J Antimicrob Agents. 2016 Jul; 48(1):19-26. PMID: 27216380.
      Citations:    
    11. VanEperen AS, Segreti J. Empirical therapy in Methicillin-resistant Staphylococcus Aureus infections: An Up-To-Date approach. J Infect Chemother. 2016 Jun; 22(6):351-9. PMID: 27066882.
      Citations:    
    12. Rao SN, Rhodes NJ, Lee BJ, Scheetz MH, Hanson AP, Segreti J, Crank CW, Wang SK. Erratum for Rao et al., treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2015 Nov; 59(11):7159. PMID: 26464400.
      Citations:    
    13. Rao SN, Rhodes NJ, Lee BJ, Scheetz MH, Hanson AP, Segreti J, Crank CW, Wang SK. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2015 Sep; 59(9):5232-8. PMID: 26077253.
      Citations:    
    14. Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013 Dec; 68(12):2921-6. PMID: 23928022.
      Citations:    
    15. Tetreault MW, Wetters NG, Aggarwal VK, Moric M, Segreti J, Huddleston JI, Parvizi J, Della Valle CJ. Should draining wounds and sinuses associated with hip and knee arthroplasties be cultured? J Arthroplasty. 2013 Sep; 28(8 Suppl):133-6. PMID: 23906868.
      Citations:    
    16. Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother. 2013 Sep; 57(9):4190-6. PMID: 23774437.
      Citations:    
    17. Segreti J, Jones RN, Bertino JS. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. J Ocul Pharmacol Ther. 2012 Feb; 28(1):3-11. PMID: 21999341.
      Citations:    
    18. Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011 Jun; 31(6):527-36. PMID: 21923436.
      Citations:    
    19. Segreti J, Garcia-Houchins S, Gorski L, Moureau N, Shomo J, Zack J, Stachnik J, Tanzi M, Moody ML. Consensus conference on prevention of central line-associated bloodstream infections: 2009. J Infus Nurs. 2011 Mar-Apr; 34(2):126-33. PMID: 21399459.
      Citations:    
    20. Della Valle C, Parvizi J, Bauer TW, Dicesare PE, Evans RP, Segreti J, Spangehl M, Watters WC, Keith M, Turkelson CM, Wies JL, Sluka P, Hitchcock K. Diagnosis of periprosthetic joint infections of the hip and knee. J Am Acad Orthop Surg. 2010 Dec; 18(12):760-70. PMID: 21119142.
      Citations:    
    21. Sikka MK, Hayden MK, Pur S, Segreti J, Harris AA, Weinstein RA, Trenholme G. Microbiologic and clinical epidemiologic characteristics of the Chicago subset of a multistate outbreak of Serratia marcescens bacteremia. Infect Control Hosp Epidemiol. 2010 Nov; 31(11):1191-3. PMID: 20923282.
      Citations:    
    22. Crank CW, Scheetz MH, Brielmaier B, Rose WE, Patel GP, Ritchie DJ, Segreti J. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study. Clin Ther. 2010 Sep; 32(10):1713-9. PMID: 21194593.
      Citations:    
    23. Segreti J. Empirical therapy for serious Gram-positive infections: making the right choice. Clin Microbiol Infect. 2009 Dec; 15 Suppl 6:5-10. PMID: 19917021.
      Citations:    
    24. Segreti J. Review of question and answer session. Int J Antimicrob Agents. 2009 Jul; 34 Suppl 1:S36-8. PMID: 19560674.
      Citations:    
    25. Harting BP, Talbot TR, Dellit TH, Hebden J, Cuny J, Greene WH, Segreti J. University HealthSystem Consortium quality performance benchmarking study of the insertion and care of central venous catheters. Infect Control Hosp Epidemiol. 2008 May; 29(5):440-2. PMID: 18419367.
      Citations:    
    26. Tverdek FP, Crank CW, Segreti J. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care. Crit Care Clin. 2008 Apr; 24(2):249-60, vii-viii. PMID: 18361944.
      Citations:    
    27. Rolston KV, Segreti J, Lamp KC, Friedrich LV. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med. 2007 Oct; 120(10 Suppl 1):S4-5. PMID: 17904949.
      Citations:    
    28. Cohen NJ, Papernik M, Singleton J, Segreti J, Eremeeva ME. Q fever in an American tourist returned from Australia. Travel Med Infect Dis. 2007 May; 5(3):194-5. PMID: 17448948.
      Citations:    
    29. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy. 2006 Mar; 26(3):347-52. PMID: 16503714.
      Citations:    
    30. Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin. 2005 Dec; 21(12):1923-6. PMID: 16368041.
      Citations:    
    31. Turner TM, Urban RM, Hall DJ, Chye PC, Segreti J, Gitelis S. Local and systemic levels of tobramycin delivered from calcium sulfate bone graft substitute pellets. Clin Orthop Relat Res. 2005 Aug; (437):97-104. PMID: 16056033.
      Citations:    
    32. Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med. 2005 Jul; 118 Suppl 7A:21S-28S. PMID: 15993674.
      Citations:    
    33. Hota BN, Pur S, Phillips L, Weinstein RA, Segreti J. Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli. Eur J Clin Microbiol Infect Dis. 2005 Jun; 24(6):405-10. PMID: 15931454.
      Citations:    
    34. Segreti J. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance. Clin Microbiol Infect. 2005 May; 11 Suppl 3:29-35. PMID: 15811022.
      Citations:    
    35. Zimmerman M, Pur S, Schmitt B, Levin S, Harris AA, Segreti J. Value of an infection control practitioner in improving infection control practices at ambulatory sites. Infect Control Hosp Epidemiol. 2004 Apr; 25(4):348-50. PMID: 15108735.
      Citations:    
    36. Toubes E, Segreti J. Treatment Options for Orthopedic Device-related Infections. Curr Infect Dis Rep. 2002 Oct; 4(5):433-438. PMID: 12228031.
      Citations:    
    37. Segreti J. Is antibiotic prophylaxis necessary for preventing prosthetic device infection? Infect Dis Clin North Am. 1999 Dec; 13(4):871-7, vii. PMID: 10579113.
      Citations:    
    38. Goodman L, Segreti J. Infectious diarrhea. Dis Mon. 1999 Jul; 45(7):268-99. PMID: 10480543.
      Citations:    
    39. Segreti J, Nelson JA, Trenholme GM. Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin Infect Dis. 1998 Oct; 27(4):711-3. PMID: 9798021.
      Citations:    
    40. File TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997 Sep; 41(9):1965-72. PMID: 9303395.
      Citations:    
    41. Segreti J, Harris AA. Acute bacterial meningitis. Infect Dis Clin North Am. 1996 Dec; 10(4):797-809. PMID: 8958169.
      Citations:    
    42. Segreti J, Meyer P, Kapell K. In vitro activity of macrolides against intracellular Legionella pneumophila. Diagn Microbiol Infect Dis. 1996 Jul; 25(3):123-6. PMID: 8902407.
      Citations:    
    43. Segreti J, Levin S. Bacteriologic and clinical applications of a new extended-spectrum parenteral cephalosporin. Am J Med. 1996 Jun 24; 100(6A):45S-51S. PMID: 8678097.
      Citations:    
    44. Fischer SA, Harris AA, Segreti J, Goodman LJ, Langkop C, Swartz M, Lollar R, Trenholme GM. Screening for Escherichia coli O157:H7 in Illinois. Clin Microbiol Infect. 1996 Mar; 1(3):175-178. PMID: 11866753.
      Citations:    
    45. Segreti J, Trenholme GM, Levin S. Antibiotic therapy in the allergic patient. Med Clin North Am. 1995 Jul; 79(4):935-42. PMID: 7791431.
      Citations:    
    46. Ellis LC, Segreti J, Gitelis S, Huber JF. Joint infections due to Listeria monocytogenes: case report and review. Clin Infect Dis. 1995 Jun; 20(6):1548-50. PMID: 7548508.
      Citations:    
    47. Segreti J, Connelly R. Effect of quinolone use on antimicrobial susceptibility patterns over a 5-year period. Drugs. 1995; 49 Suppl 2:185-7. PMID: 8549297.
      Citations:    
    48. Segreti J, Kraatz J, Goldman M, Trenholme GM. In vitro activity of FK-037. A parenteral cephalosporin. Diagn Microbiol Infect Dis. 1994 Nov; 20(3):175-9. PMID: 7874887.
      Citations:    
    49. Segreti J, Kapell KS. In vitro activity of dirithromycin against Chlamydia trachomatis. Antimicrob Agents Chemother. 1994 Sep; 38(9):2213-4. PMID: 7811051.
      Citations:    
    50. Segreti J, Goodman LJ, Trenholme GM. In vitro activity of new quinoxaline compounds against Campylobacter species and Clostridium difficile. Diagn Microbiol Infect Dis. 1993 Aug-Sep; 17(2):177-9. PMID: 8243041.
      Citations:    
    51. Levin JM, Nelson JA, Segreti J, Harrison B, Benson CA, Strle F. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents. Antimicrob Agents Chemother. 1993 Jul; 37(7):1444-6. PMID: 8363373.
      Citations:    
    52. Segreti J, Gootz TD, Goodman LJ, Parkhurst GW, Quinn JP, Martin BA, Trenholme GM. High-level quinolone resistance in clinical isolates of Campylobacter jejuni. J Infect Dis. 1992 Apr; 165(4):667-70. PMID: 1313069.
      Citations:    
    53. Segreti J. Fluoroquinolones for the treatment of nongonococcal urethritis/cervicitis. Am J Med. 1991 Dec 30; 91(6A):150S-152S. PMID: 1662887.
      Citations:    
    54. Segreti J. In vitro activity of temafloxacin against pathogens causing sexually transmitted diseases. Am J Med. 1991 Dec 30; 91(6A):24S-26S. PMID: 1662891.
      Citations:    
    55. Segreti J, Hirsch DJ, Harris AA, Kapell KS, Orbach H, Kessler HA. In vitro activity of tosufloxacin (A-61827; T-3262) against selected genital pathogens. Antimicrob Agents Chemother. 1990 Jun; 34(6):971-3. PMID: 2118330.
      Citations:    
    56. Goodman LJ, Trenholme GM, Kaplan RL, Segreti J, Hines D, Petrak R, Nelson JA, Mayer KW, Landau W, Parkhurst GW, et al. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med. 1990 Mar; 150(3):541-6. PMID: 2178582.
      Citations:    
    57. Segreti J, Nelson JA, Goodman LJ, Kaplan RL, Trenholme GM. In vitro activities of lomefloxacin and temafloxacin against pathogens causing diarrhea. Antimicrob Agents Chemother. 1989 Aug; 33(8):1385-7. PMID: 2802563.
      Citations:    
    58. Segreti J, Gvazdinskas LC, Trenholme GM. In vitro activity of minocycline and rifampin against staphylococci. Diagn Microbiol Infect Dis. 1989 May-Jun; 12(3):253-5. PMID: 2791487.
      Citations:    
    59. Segreti J, Kessler HA, Kapell K, Trenholme GM. In vitro activity of lomefloxacin (SC 47111 or NY-198) against Chlamydia trachomatis strains. Diagn Microbiol Infect Dis. 1989 May-Jun; 12(3 Suppl):87S-88S. PMID: 2791503.
      Citations:    
    60. Segreti J. Nosocomial infections and secondary infections in sepsis. Crit Care Clin. 1989 Jan; 5(1):177-89. PMID: 2647224.
      Citations:    
    61. Segreti J, Kessler HA, Kapell KS, Trenholme GM. In vitro activities of temafloxacin (A-62254) and four other antibiotics against Chlamydia trachomatis. Antimicrob Agents Chemother. 1989 Jan; 33(1):118-9. PMID: 2712543.
      Citations:    
    62. Segreti J, Harris AA, Kessler HA, Busch K. Neuropsychiatric complications of human immunodeficiency virus infection. Compr Ther. 1988 Jul; 14(7):9-15. PMID: 3060307.
      Citations:    
    Segreti's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (247)
    Explore
    _
    Co-Authors (12)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _